Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

NCT04925960 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Due to futility

Conditions

Pmm2-CDG
Phosphomannomutase 2 Deficiency
Phosphomannomutase 2 Congenital Disorder of Glycosylation
Phosphomannomutase II Congenital Disorder of Glycosylation
Phosphomannomutase II Deficiency

Interventions

DRUG: Epalrestat
DRUG: Placebo

Sponsor

Maggie's Pearl, LLC